Summary by Moomoo AI
On February 21, 2024, Aclarion, Inc., a healthcare technology company, filed an amendment to its S-1 registration statement in connection with a proposed public offering. This amendment included audited financial statements for the fiscal years ended December 31, 2023, and December 31, 2022. The financial statements, which were furnished as Exhibit 99.1 to the Current Report on Form 8-K, revealed that Aclarion has been experiencing recurring losses from operations and has a shareholders' equity deficit, raising substantial doubt about its ability to continue as a going concern. The audited financial statements were prepared assuming the company will continue to operate, and no adjustments have been made that might result from the outcome of this uncertainty. The report was signed by John Lorbiecki, an authorized representative of Aclarion, Inc.